Navigation Links
Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
Date:7/30/2013

SAN FRANCISCO, July 30, 2013 /PRNewswire/-- Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.  The Phase 3 study, also known as the BEACON trial, is evaluating etirinotecan pegol versus a single-agent treatment of physician's choice for the treatment of locally recurrent or metastatic breast cancer.  Etirinotecan pegol is the first long-acting topoisomerase I inhibitor designed to concentrate in tumor tissue to provide sustained tumor suppression throughout the entire chemotherapy cycle."Strong interest in etirinotecan pegol and the BEACON study from investigators and patients has allowed us to rapidly complete our recruitment and enrollment," said Robert Medve, MD, Senior Vice President and Chief Medical Officer of Nektar Therapeutics. "We recognize the high unmet need for new treatment options in the metastatic breast cancer setting, particularly among patients with HER2-negative breast cancer whose disease has progressed following anthracycline, taxane and capecitabine therapies. The primary endpoint in the BEACON study is survival and as we have previously announced, we plan to conduct an interim futility analysis for the BEACON study in the first quarter of next year with topline survival data to be available around the end of 2014."

Positive Phase 2 data for etirinotecan pegol was previously announced and presented at the ASCO 2011 Breast Cancer Symposium (Garcia et. al., ASCO 2011).  Etirinotecan pegol achieved a confirmed objective response rate by RECIST of 29 percent. In addition, 71 percent of patients in the study had no tumor progression, defined as complete response (CR), partial response (PR) and stable disease (SD), as measured by RECIST criteria.
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
2. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
5. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
6. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
7. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
10. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
11. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Fla. , July 11, 2014  Rock Creek ... biotechnology company, today announced that the Food and Drug ... will provide comments on RCP,s Investigational New Drug ("IND") ... clinical trial in the US. Dr. ... agency,s review and comments on our IND. When we ...
(Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
(Date:7/11/2014)... Show organisers report ... Expo 2014 were a brand new audience ... London , plus a 10% increase ...      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ) ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
(Date:7/14/2014)... (PRWEB) July 14, 2014 Top nutritional ... expansion of its Quality Control and Assurance Department. As ... hired two additional, highly-qualified quality assurance (QA) and quality ... standards for which IQ Formulations has become known. ... technicians bring decades of stellar experience and qualifications to ...
(Date:7/14/2014)... BCC Research ( http://www.bccresearch.com ) ... GLOBAL MARKETS , the global synthetic biology market ... in 2018, with a five-year compound annual growth ... the fastest growing segment, with anticipated $9.7 billion ... in the pharmaceutical/diagnostics, chemical, energy, and agricultural industries ...
(Date:7/14/2014)... 13, 2014 (HealthDay News) -- Along with improving vision, ... Alzheimer,s disease and other types of dementia, a new ... of life, the researchers said. "These preliminary results ... benefits for people with dementia and their loved ones, ... Case Western Reserve University and University Hospitals Case Medical ...
(Date:7/14/2014)... 2014 (HealthDay News) -- Stress can slow a woman,s metabolism ... study included 58 women, average age 53, who were asked ... a meal than included 930 calories and 60 grams of ... took the women to burn off those calories and fat. ... events during the previous 24 hours burned 104 fewer calories ...
(Date:7/14/2014)... Skin M.D. by The ... Monday, July 14th, located at 45 East Putnam ... all week through Saturday, July 19th, with free ... to attend. The business is owned by Karen ... weight loss services, and sells high-end industry leading ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Expands Quality Control and Assurance Department 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Stress May Leave You Heading to the Cookie Jar 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3
... ... News reports that detainees being held by US forces at an undisclosed second detention ... temperature manipulation, and sleep deprivation. , ... Cambridge, MA (Vocus) -- Physicians for Human Rights (PHR) today called ...
... protective, experts say, , TUESDAY, May 11 (HealthDay News) -- ... offer the same protection against falls and fractures in older ... has found. , What,s more, the research suggests that when ... it actually increases the risk of falls by 15 percent ...
... As the United States moves toward the goal of a ... the Regenstrief Institute provides a framework for evaluating the costs, ... the health internet. The study, which appears in ... Medical Informatics Association , also reports on the initial assessment ...
... ... than serially, to deliver highly responsive, customer-oriented presentations. , ... London, UK (PRWEB) May 11, ... now available for Microsoft® Office PowerPoint®. This new software enables PowerPoint authors ...
... African Americans, colorectal cancer is the third most common cause ... a 90 percent cure rate, yet screening rates are much ... researchers have tried to figure out why, but most have ... haven,t explored the differences in what keeps African American men ...
... ... Take Championship Title , ... -- Human Touch ®, the U.S. market leader of innovative massage chairs, Perfect Chair® ... Pro Tim Clark for his first PGA TOUR victory in his career at one ...
Cached Medicine News:Health News:President Obama Must Investigate Reports of Detainee Abuse at Bagram Air Base 2Health News:Once-A-Year Vitamin D Megadose Ups Fracture Risk: Study 2Health News:Once-A-Year Vitamin D Megadose Ups Fracture Risk: Study 3Health News:Measuring success: Regenstrief helps assess value of investment in health info tech 2Health News:GMARK Launches World's First Web-Like, PowerPoint Navigation Software 2Health News:Exploring gender differences in colorectal cancer screenings 2Health News:Human Touch Brand Ambassador and PGA Pro Tim Clark Wins First PGA TOUR Victory at PLAYERS Championship 2Health News:Human Touch Brand Ambassador and PGA Pro Tim Clark Wins First PGA TOUR Victory at PLAYERS Championship 3
PhenoPath Laboratories provides screening, diagnostic, and prognostic testing services to hospitals, physician offices, surgery centers, biopharmaceutical companies and research institutions nationwi...
the LabOne Healthcare Group markets laboratory testing to physicians, patients, managed care companies, self-insured employers, wellness companies and hospitals....
... hemostatic gauze for a variety of inpatient and ... is easy to handle and can be customized ... that are often a challenge faced by obstetricians ... to control bleeding in outpatient procedures such as ...
Sharp tipped straight scissors. For cutting in the iris plane or cutting peripheral membranes. May also be useful in ROP cases....
Medicine Products: